Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Birchview Capital and Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (NASDAQ:SLNO): Matthew Strobeck’s Birchview Capital filed an amended 13D.

You can check out Birchview Capital’s latest holdings and filings here.

Please follow Birchview Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Birchview Capital or update its stock holdings.

Matthew Strobeck
Matthew Strobeck
Birchview Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Birchview Capital 1,180,463 0 1,180,463 0 1,180,463 6.166%
Matthew Strobeck
Matthew Strobeck
Birchview Capital

Page 1 of 4 – SEC Filing



Washington, D.C. 20549



Under the Securities Exchange Act of

(Amendment No.__ )*


(Name of Issuer)

Common Stock

(Title of Class of Securities)


(CUSIP Number)

December 15, 2017

(Date of Event which Requires Filing of
this Statement)

Check the appropriate box to designate the rule pursuant to
which this Schedule is filed:

x  Rule 13d-1(b)
¨  Rule 13d-1(c)
¨  Rule 13d-1(d)

*The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required on the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes).

Continued on following pages

Page 1 of 4 Pages

Follow Soleno Therapeutics Inc (NASDAQ:SLNO)
Trade (NASDAQ:SLNO) Now!